Phase II Study to Evaluate the Activity of Commercially Available Molecularly Matched Targeted Therapies in Selected Tumor Types Based on Genomic Alterations
Summary
The purpose of this phase II study is to examine the anti-tumor activity of afatinib and regorafenib to treat patients who were previously profiled with next-generation sequencing technology and who failed first-line treatment for one of the following tumor types: non-small cell lung cancers; urothelial cancer; non-colon gastrointestinal cancers, and upper aerodigestive tract cancer.
Next-generation sequencing is NOT offered as part of this study. Patients must have previously received next-generation sequencing prior to study entry.
General Information
NCT#: NCT02795156
Study ID: SCRI PRO 10
Trial Phase: Phase II
Trial Sponsor: Sarah Cannon Research Institute (SCRI)
Therapies Used in This Trial: Cabozantinib, Regorafenib, Afatinib
Sign In